Chapter 5 —— 148 —— 37. Ricobaraza A., Gonzalez-Aparicio M., Mora-Jimenez L., Lumbreras S., HernandezAlcoceba R. High-capacity adenoviral vectors: expanding the scope of gene therapy. Int. J. Mol. Sci. 2020; 21:3643. 38. Wang Q, Liu J, Janssen JM, Le Bouteiller M, Frock RL, Gonçalves MAFV. Precise and broad scope genome editing based on high-specificity Cas9 nickases. Nucleic Acids Res. 2021 49:1173-1198. 39. Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, Majeti R, Weinberg KI, Porteus MH. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016 539:384-389. 40. Pavani G, Fabiano A, Laurent M, Amor F, Cantelli E, Chalumeau A, Maule G, Tachtsidi A, Concordet JP, Cereseto A, Mavilio F, Ferrari G, Miccio A, Amendola M. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells. Blood Adv. 2021 5:1137-1153. 41. McColl-Carboni A, Dollive S, Laughlin S, Lushi R, MacArthur M, Zhou S, Gagnon J, Smith CA, Burnham B, Horton R, Lata D, Uga B, Natu K, Michel E, Slater C, DaSilva E, Bruccoleri R, Kelly T, McGivney JB 4th. Analytical characterization of full, intermediate, and empty AAV capsids. Gene Ther. 2024 31:285-294. 42. Frock RL, Hu J, Meyers RM, Ho YJ, Kii E, Alt FW. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat. Biotechnol. 2015 33:179186. 43. Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPRCas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018 36:765771. 44. Lombardo A, Cesana D, Genovese P, Di Stefano B, Provasi E, Colombo DF, Neri M, Magnani Z, Cantore A, Lo Riso P, Damo M, Pello OM, Holmes MC, Gregory PD, Gritti A, Broccoli V, Bonini C, Naldini L. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat. Methods 2011 8:861-869. 45. Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, Kommineni S, Chen J, Sondey M, Ye C, Randhawa R, Kulkarni T, Yang Z, McAllister G, Russ C, Reece-Hoyes J, Forrester W, Hoffman GR, Dolmetsch R, Kaykas A. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018 24:939-946. 46. Chen X, Tasca F, Wang Q, Liu J, Janssen JM, Brescia MD, Bellin M, Szuhai K, Kenrick J, Frock RL, Gonçalves MAFV. Expanding the editable genome and CRISPR-Cas9 versatility using DNA cutting-free gene targeting based on in trans paired nicking. Nucleic Acids Res. 2020 48:974-995.
RkJQdWJsaXNoZXIy MTk4NDMw